Tepezza Lawsuit Payout: What Claimants Can Expect (2026)

Is There a Tepezza Settlement Yet?

Not yet. Based on the court records we reviewed, no one had announced a global Tepezza settlement – a single deal covering all the cases – as of October 2026. No jury has reached a verdict either. The federal cases sit in MDL No. 3079 in the Northern District of Illinois before Judge Thomas M. Durkin. As of October 1, 2026, the Judicial Panel on Multidistrict Litigation listed 279 cases still pending, out of 289 filed in total.

The main defendant is Horizon Therapeutics USA, Inc. Amgen completed its purchase of Horizon on October 6, 2023, so any deal would now involve an Amgen company.

The court built settlement talks into the case. Case Management Order No. 4, a July 2024 scheduling order, required court-ordered mediation to begin around August 1, 2024, with more sessions every 90 days after that. Mediation is a private negotiation led by a neutral go-between. It does not force anyone to settle.

The trial calendar has stalled. On October 1, 2025, Chief Magistrate Judge M. David Weisman removed every date tied to the test trials after an off-the-record talk with both sides. In February 2026, legal publisher HarrisMartin reported that the court cancelled a February 12 status hearing and issued a common-benefit fee protocol. That protocol sets rules for paying the lawyers who lead the shared work. We have not found a public order setting new trial dates, and neither side has confirmed a deal.

How Much Tepezza Cases May Pay

Right now, no one can say what a Tepezza case is worth. No court or company has released official figures for any Tepezza lawsuit payout, and no settlement program exists to publish them. The neat payout tiers you may see online come from law firm projections. They are not court figures, and we would treat them with caution.

These cases are also not a class action. In a multidistrict litigation (MDL), one judge handles shared pretrial work, but each person keeps their own case. If a deal comes, payouts would most likely turn on each person's own injury and proof, not one flat amount for everyone.

Keep in mind that any settlement figure is a gross amount – the total before deductions. Attorney fees and case costs usually come out first. Many MDLs also set aside a small share of each recovery under a common-benefit order to pay the lawyers who led the shared work. Health insurers and Medicare that paid for hearing care may also have a right to be repaid, and Medicaid can take part of a settlement for the care it covered.

Who May Qualify for a Payout

Generally speaking, people who may qualify had Tepezza infusions and then got a doctor's diagnosis of hearing loss, tinnitus (ringing in the ears), or another lasting hearing problem. A lawyer will usually also review your hearing history from before treatment, since the claim rests on showing the problem started or worsened after the drug.

The court adds its own paperwork. Under Case Management Order No. 3, every plaintiff must serve a Plaintiff Profile Form and signed forms that release their medical records.

Timing may matter too. On July 17, 2023, the FDA approved a revised Tepezza label warning that hearing loss may be permanent and telling doctors to check hearing before, during, and after treatment. Because these are failure-to-warn claims, what the label said when you got treatment could come up.

What Could Raise or Lower a Tepezza Claim's Value

Several factors typically shape what a hearing loss claim is worth:

• How lasting the damage is. Permanent loss usually weighs more than symptoms that fade. In a 2022 study in the American Journal of Ophthalmology, only 45.5% of the patients who noticed hearing loss saw it clear up.
• Hearing tests. Audiograms (hearing test results) from before and after infusions can show a clear drop and make the link easier to prove.
• Other possible causes. Age, noise exposure, and earlier ear problems can blur the picture. A 2024 study of hearing tests in Ophthalmology found older patients were hit harder.
• Costs and daily impact. Hearing aids, cochlear implants, specialist visits, and missed work help show what the injury cost you.
• State law. The state law that governs a claim can decide whether it survives. In October 2024, the court dismissed one test case under Michigan law, which at the time barred product liability suits against makers of FDA-approved drugs.
• Filing deadline. Every state sets a time limit to file an injury claim, and a late claim may get nothing at all.

Court Rulings That Could Shape Settlement Value

Bellwether trials, the early test trials, and key court rulings often set the price of mass tort deals, because they show how juries and judges view the evidence. No Tepezza jury has reached a verdict yet. In August 2025, the court reset four test trials to run from August 3, 2026 through February 1, 2027. The court struck those dates in October 2025, before the first trial began.

Earlier rulings cut both ways. In January 2025, Judge Durkin let the failure-to-warn claims move forward but dismissed claims that Horizon defectively designed Tepezza. Failure to warn is the heart of these cases, so the core claim that drives any settlement is still in play.

Talk to a Lawyer About a Tepezza Claim

If you developed hearing loss or tinnitus after Tepezza infusions, a lawyer can review your records and explain how the case may affect you. ConsumerShield matches you directly with experienced local lawyers who specialize in cases like yours.